[Virginia] Specialty pharmacy precertification list expands
Act
by Jan 1, 2027
Effective date
Jan 1, 2027
Identified
Oct 14, 2026
Summary
Anthem Blue Cross and Blue Shield (Virginia) is expanding its specialty pharmacy precertification requirements for Medicare Advantage members. Effective January 1, 2027, step therapy precertification will apply to multiple Part B medications (denosumab, bendamustine, pemetrexed, and hyaluronate products). Additionally, effective February 1, 2027, three new specialty drugs (golimumab-sldi, bevacizumab-vikg, and isatuximab-irfc) will require precertification review. Noncompliance with these new requirements may result in claim denial.
Get alerts when payers change rules like this one
We check Anthem BCBS and other payers every day and email you when a change matches your specialty and state.
01Billing team must implement step therapy precertification review for Part B medications listed in Clinical Criteria Guidelines (CC-0027, CC-0310, CC-0116, CC-0094, CC-0005) in the billing system.
02Step therapy will apply upon initiation of precertification in addition to medical necessity review and will NOT apply to members already receiving these medications.
03By February 1, 2027: Billing team must update prior authorization workflows to require precertification for HCPCS codes C9399/J3590 (Immgolis Intri and Lytenava) and C9399/J9999 (Sarclisa Escena) for Anthem Medicare Advantage members in Virginia.
04Reference the Clinical Criteria Guidelines available on the Anthem provider website.
If missed: Failure to obtain required precertification may result in claim denial and member ineligibility for reimbursement.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.